In a world where threats lurk around every digital corner, safeguarding sensitive information has never been more crucial. Recent events, such as the Change Healthcare cyber-attack, serve as stark reminders of the pressing need for robust cybersecurity measures.
As the biologics and biosimilars market continues to grow, questions emerge about what to do at the pharmacy counter. Audit expert Trent Thiede, PharmD, MBA, president, PAAS National, will be at the 2024 Multiple Locations Conference to discuss biosimilars, interchangeability, and appropriate DAW codes.
If you own multiple locations (or want to branch out), the 2024 NCPA Multiple Locations Conference has the solutions you need to expand your practice and push profitability to new heights. One opportunity you might like is to hear Trent Thiede, PharmD, MBA, and president of PAAS National, talk about “How Biosimilars Are Changing the Way You Practice.” He’ll address all the questions that emerged about what to do at the counter when you’re faced with biosimilars, interchangeability, and the appropriate DAW codes.
Pharmacies submitting a 340B identifier incur a high administrative burden and financial risk, and NCPA is hoping to do something about it. NCPAs Director of Policy and Regulatory Affairs Steve Postal, as well as NCPA 3040B Task Force members Trent Thiede and Greg Turner, recently joined a roundtable on 340B transparency organized by the Reservoir Communications Group.
Pharmacies face extra audit burdens that threaten their existence modernhealthcare.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernhealthcare.com Daily Mail and Mail on Sunday newspapers.